Merck & Co., Inc. (MRK)
Merck prevails in Gardasil safety litigation
A federal judge has ruled in favor of Merck in litigation accusing the drugmaker of concealing the risks of Gardasin, a vaccine to prevent cervical and other fatal cancers.
Merck opens vaccine manufacturing facility in North Carolina
Merck said on Tuesday it has opened a new $1 billion, 225,000-square-foot facility dedicated to vaccine manufacturing at its Durham, North Carolina, site.
Merck (MRK) Ascends While Market Falls: Some Facts to Note
Merck (MRK) closed at $94 in the latest trading session, marking a +0.87% move from the prior day.
Merck (MRK) Up 3.9% Since Last Earnings Report: Can It Continue?
Merck (MRK) reported earnings 30 days ago. What's next for the stock?
New version of Merck's cancer drug faces patent battle, WSJ reports
Merck has asked the U.S. patent office to reconsider patents that could prevent it from selling a new version of its cancer drug Keytruda, the Wall Street Journal reported on Wednesday.
Merck & Co., Inc. (MRK) Presents at TD Cowen 45th Annual Health Care Conference (Transcript)
Start Time: 14:30 January 1, 0000 3:05 PM ET Merck & Co., Inc.
These S&P 500 Stocks Have Low P/E Ratios — Time to Buy?
Purchasing stocks at the right time can maximize your return on investment, especially if you plan to buy and hold shares toward a short-term or medium-term financial goal. A stock's P/E ratio can give you an immediate idea of whether a stock is trading at, below or above fair value.
Merck (MRK) Exceeds Market Returns: Some Facts to Consider
Merck (MRK) closed the most recent trading day at $92.25, moving +1.84% from the previous trading session.
Merck Slips 8% in a Month: Should You Buy, Hold or Sell the Stock?
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.
Merck's Oncology Strength: Beating Wall Street Again
On February 4, Merck released financial results for Q4 2024, which, as in previous quarters, once again beat analysts' expectations. This was driven by a strong performance by its oncology franchise, which posted sales of $8.73 billion, up 19.7% from Q4 2023 and 5.7% from Q3 2024. Thanks in part to the label expansions for Keytruda, its sales grew by 18.6% year on year.
US drugmaker Merck to boost workforce in India, executive says
Drugmaker Merck , known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by the end of the year, a senior company executive said on Wednesday.
Merck expects cancer therapy Keytruda to be part of government price setting in 2026
Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government price setting, which would become effective on January 1, 2028.
